Four stories defined the week in biopharma: a new government price hub, a profit shift between the two giants of weight loss, an FDA crackdown on copycat GLP-1s, and another sizable acquisition.
TrumpRx
Donald Trump’s administration launched TrumpRx.gov as a hub directing cash-pay patients to discounted drugs through coupons and manufacturer links rather than direct selling. The site has not rolled out all planned drugs yet, and many of the most visible discounts are on GLP-1 drugs. A sample page offers 43 drugs sorted by best deal, with Cetrotide at $22.50 (down from $316.12, 93% off), the Wegovy pill starting at $149.00 (down from $1,349.02, 89% off) and Bevespi at $51.00 (down from $458.05, 89% off).
This is effectively a new pricing reference point in the US cash-pay channel. Watch how it changes manufacturer net pricing strategies and the price pressure on big pharma.
Novo and Lilly
A chart from The Economist showing net profit in billions of dollars for Novo Nordisk and Eli Lilly from 2020 through 2025 captures the GLP-1 profit shock. Novo led the early obesity boom in 2023 and 2024 with a great margin. The 2025 projections flip that, with Lilly overtaking as scale kicks in.
Novo is warning that profits and sales in 2026 could decline amid price pressure and fierce competition, while Lilly is still guiding growth. Both face the same margin headwinds from cash-pay price caps, compounding crackdowns and TrumpRx-driven reference pricing. This is current market sentiment, not a locked-in projection. Expect more fluctuations as the year goes on, because pricing pressure, access and channel shifts, supply and regulatory enforcement can all swing margins.
Hims & Hers versus the FDA
Shortly after Hims & Hers Health, a telehealth platform that provides personalized online medical consultations and prescription treatments for various conditions, launched a very low-cost copycat GLP-1 pill, it faced regulatory blowback almost immediately from the FDA. The company has since taken the GLP-1s off the market, with some reports saying Novo Nordisk signaled potential legal action. Hims’ stock fell about 15% on the news around February 6 amid legal and regulatory pressure, including the FDA probe and enforcement angle. It closed at $23.02 on February 6, down 14.64% over five days, and slid further to $19.37 after hours.
This shows the serious action being taken by the FDA against companies marketing illegal copycat versions of weight loss drugs, and it highlights the safety, quality and legal concerns around mass-compounded GLP-1s.
GSK buys Rapt
GSK has agreed to acquire Rapt Therapeutics for about $2.2B in a $58-per-share cash deal, mainly for Rapt’s long-acting anti-IgE antibody ozureprubart (RPT904). IgE drives allergic reactions, and the half-life-extended antibody is in Phase 2b, the mid-stage trial and dose selection phase, for food allergies. Its differentiator is less frequent dosing, targeting roughly every 12 weeks.
The acquisition deepens GSK’s respiratory and immunology portfolio while keeping the biotech M&A scene hot. Keep an eye out for further clinical trial updates and any progression in IgE tests.